ArticleLiver cancer2026

Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma.

Lorenza Rimassa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.